The concept of "patients participating in drug research and development" is valued

Pharmaceutical executives believe that greater patient and public participation can improve drug research and development, according to a new study The study, published in BMJ open, is the first in the world to explore the ideas of executives of many European pharmaceutical companies on patients and public participation in drug research and development At present, the participation of patients in drug research and development is still a new thing The research projects and organizations that patients actively participate in are mainly public research projects such as UK's National Institute for health research, such as rare diseases and other areas with limited existing therapeutic drugs However, the pharmaceutical industry is increasingly interested in how to make drug research and development more patient-centered According to a survey conducted in 2014, 73% of employees in the pharmaceutical industry believe that the pharmaceutical industry needs to change the relationship with patients; meanwhile, 85% of employees believe that the growing patient-centered research is very important for the sustainable development of drugs In the research report released this time, the researchers interviewed 21 industry experts from 11 pharmaceutical companies, including 4 from the UK, 4 from Spain, 8 from Poland, and the other representatives were Pan European roles, gaining their attitudes towards patients and public participation in drug research and development (PPI) The interview covered various disciplines of drug research and development, including registration and medical affairs, communication, policy and patient relations, and research projects The research team is made up of University of Manchester, GlaxoSmithKline and market researchers Most experts hold a positive attitude towards PPI, and many people are optimistic that more and more patients and public participation will make a positive contribution to the process of drug research and development At the same time, the interviewees also emphasized the obstacles faced by PPI in the future, including: in a sense, this concept is too abstract, especially when persuading the leaders in the pharmaceutical field of its importance and benefits; the organizational norms of this research method are also the obstacles faced by PPI at present; at the same time, let those patients and the public who hold a negative attitude towards the pharmaceutical field It is also difficult for people to participate in drug research and development The study is part of an extension of the European patient treatment innovation project (eupati), a patient led initiative initiated by teams from academia, patient advocacy organizations and the pharmaceutical industry "Patients need to be partners in drug development, not just research," said Jane Griffiths, President of Janssen's Europe, Middle East and Africa affairs Due to cultural conservatism and concerns about drug registration, the pharmaceutical industry is a bit reticent about patients' direct participation in clinical trials But this situation is changing, and as we seek to understand and integrate patients' perspectives, the eupati project will provide tools and knowledge for patients to participate meaningfully in drug development " Compiled by / Shao Jianguo source / pharmafile